Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II intraperitoneal BioTTT001 for peritoneal metastatic carcinoma
ChiCTR2300069322Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- May 2023
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BioTTT001 in primary peritoneal cancer (PPC), sponsored by First Hospital of China Medical University. Primary endpoint: Progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
BioTTT001
03
Conditions
primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2300069322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069322.